Novartis and collaborators discover new dual-acting class of antimalarial compounds with potential to both prevent and treat malaria infections
17 November 2011 | By Novartis
Discovery of a new class of dual-acting antimalarial compounds...
List view / Grid view
17 November 2011 | By Novartis
Discovery of a new class of dual-acting antimalarial compounds...
9 November 2011 | By Novartis
Novartis announced the appointment of Timothy Wright...
7 November 2011 | By Novartis
New pivotal Phase III data announced...
24 October 2011 | By Novartis
Positive results from three Phase II trials...
17 October 2011 | By Novartis
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
27 September 2011 | By Novartis
Novartis has received regulatory approval in Japan for once-daily Gilenya (fingolimod)...
27 September 2011 | By Novartis
Novartis has presented new Phase III data at the ERS congress...
26 September 2011 | By Novartis
Afinitor® more than doubled the time women lived without tumor growth...
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
13 September 2011 | By Novartis
Alcon to accelerate growth through Novartis strength in market access, reimbursement, and research capability...
8 September 2011 | By Novartis
The European Commission has approved Votubia® (everolimus) tablets* for the treatment of patients aged 3 years and older...
5 September 2011 | By Novartis
The European Commission has approved Afinitor® (everolimus) tablets...
31 August 2011 | By Jerome Giovannoni and J.M. Peltier, Novartis
The constant growth of compound collections, combined with screening efforts on more challenging targets, is creating an increasing demand for quality control in order to ensure the integrity of the compound solutions being tested. This is true throughout the early drug discovery pipeline, from hit identification to lead nomination. Novartis…
27 July 2011 | By Teva UK Ltd
We are pleased to announce the launch of generic letrozole film-coated tablets...